EN
HI
Sun Pharmaceutical Industries Share price
SUNPHARMA
1906.1
23.90 (-1.24%)NSE
BSE
Last updated on 17 Aug, 2026 | 11:56 IST
Sun Pharmaceutical Industries share price chart
Sun Pharmaceutical Industries Share Key Metrics
Volume
5.33 L
Market Cap
463071.65 CR
LTQ@LTP
21@1906.10
ATP
1913.76
Var Margin
12.5 %
Circuit Range
1737-2123
Delivery %
69.2 %
Value
101.98 CR
ASM/GSM
No
Market Lot
1
Summary
SUNPHARMA stock price is ₹1906.1 as of 17 Aug, 2026. The stock intraday movement has stayed between ₹1900.50 and ₹1949.80, while Sun Pharmaceutical Industries share price 52 week high low is ₹1548.00 & ₹2046.90.
In terms of trading activity, SUNPHARMA share price has recorded a volume of 5,32,902 shares. The Sun Pharmaceutical Industries has a market cap of ₹2399334970. The stock’s Average Traded Price (ATP) stands at ₹1913.76, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 21 @ ₹1906.10.
The Sun Pharmaceutical Industries upper circuit limit is ₹2123.00 & The Sun Pharmaceutical Industries lower circuit limit is ₹1737.00, with a Value of ₹101.98 CR. The Delivery Percentage for the day is 69.2%.
Additionally, the share currently falls under the No framework, and trades with a market lot size of ₹1.
Sun Pharmaceutical Industries Resistance and Support
Pivot 1927.23
Resistance
First Resistance
1939.76
Second Resistance
1949.53
Third Resistance
1962.06
Support
First Support
1917.46
Second Support
1904.93
Third Support
1895.16
Sun Pharmaceutical Industries Futures & Options
1906.1
-23.9 (-1.24%)
Sun Pharmaceutical Industries Option Chain
View Price, OI, Greeks & More...
25AUG26
1912.30
-14.90 (0.77%)
29SEP26
1922.90
-15.70 (0.81%)
27OCT26
1937.80
-10.70 (0.55%)
SUNPHARMA|25AUG26 CE 1900.00
27.40
-10.6 (-27.89%)
SUNPHARMA|25AUG26 PE 1920.00
24.3
6.7 (38.07%)
Sun Pharmaceutical Industries Shareholding Pattern
View More- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Segment
Percent
Total Promoters
54.48%
Mutual Fund
12.84%
Insurance
7.02%
Foreign Institutional Investors
14.54%
Domestic Institutional Investors
2.3%
Retail
8.82%
Others
0%
Total Promoters
MAR '26
54.48%
JUN '26
54.48%
Sun Pharmaceutical Industries Corporate Actions
| Date | Agenda |
|---|---|
| 2026-07-31 | Quarterly Results |
| 2026-05-22 | Audited Results & Final Dividend |
| 2026-01-31 | Quarterly Results & Interim Dividend |
| 2025-11-05 | Quarterly Results |
| 2025-07-31 | Quarterly Results |
| 2025-05-22 | Audited Results & Final Dividend |
| 2025-01-31 | Quarterly Results & Interim Dividend |
| 2024-10-28 | Quarterly Results |
| Ex Date | Record Date | |
|---|---|---|
| 2026-07-07 | 2026-07-07 | View More |
Sun Pharmaceutical Industries News
Sun Pharmaceutical Industries Ltd - 524715 - Update On Lipitor Antitrust Litigation
Sun Pharmaceutical secured a significant favorable development in the US Lipitor antitrust litigation. The US Court of Appeals affirmed the District Court's summary judgment in favor of the company and denied class certification to plaintiffs, substantially closing the matter.
Aug 17 2026 08:40:23
Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Sun Pharmaceutical Industries Ltd has scheduled three analyst and institutional investor meetings in Mumbai on August 10, 12, and 13, 2026. The company has clarified that no unpublished price sensitive information will be disclosed during these engagements.
Aug 05 2026 16:34:27
Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Credit Rating
CRISIL Ratings has reaffirmed Sun Pharmaceutical's long-term bank facilities rating at 'CRISIL AAA/Stable' and removed the 'Rating Watch with Developing Implications' status, indicating improved certainty.
Aug 05 2026 09:18:15
Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharma received regulatory approval from ANVISA to manufacture and market semaglutide injection in Brazil. This expands its diabetes portfolio into the approximately $413 million Brazilian injectable market, launching with Hypera Pharma.
Jul 29 2026 22:00:17
Sun Pharmaceutical Industries Ltd - 524715 - Update On Nidlegy
Sun Pharmaceutical's partner, Philogen, has resubmitted the Marketing Authorization Application (MAA) for Nidlegy™ to the European Medicines Agency (EMA). This updated submission is for the neoadjuvant treatment of locally advanced, fully resectable melanoma, and incorporates enhanced clinical data from the Phase III PIVOTAL study and addresses previous regulatory questions.
Jul 27 2026 16:00:08
Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharma announced that Organon shareholders have approved the proposed acquisition, where Organon will become a wholly-owned subsidiary of Sun Pharma Holdings USA, Inc. This approval is a significant milestone towards completing the transaction, which remains subject to customary closing conditions and regulatory approvals.
Jul 24 2026 08:50:33
Read More
Sun Pharmaceutical Industries Management
| Name | Position |
|---|---|
| Anoop Deshpande | Company Secretary & Compliance Officer |
| Dilip S Shanghvi | Chairman & Managing Director |
Sun Pharmaceutical Industries Similar Stocks
Divi's Laboratories Ltd.
8489.00
12.00 (0.14%)
Torrent Pharmaceuticals Ltd.
4854.50
21.50 (0.44%)
Apollo Hospitals Enterprise Ltd.
8886.50
-34.00 (0.38%)
Cipla Ltd.
1428.50
-21.50 (1.48%)
Zydus Lifesciences Ltd.
1150.70
15.50 (1.37%)
Lenskart Solutions Ltd.
608.60
-3.25 (0.53%)
Lupin Ltd.
2223.50
-11.50 (0.51%)
Dr. Reddy's Laboratories Ltd.
1190.70
-9.30 (0.78%)
Mankind Pharma Ltd.
2396.30
-28.90 (1.19%)
Max Healthcare Institute Ltd.
999.30
-9.30 (0.92%)
Sun Pharmaceutical Industries FAQs
The Buying Price of Sun Pharmaceutical Industries share is 1906.1 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.
To buy Sun Pharmaceutical Industries stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Sun Pharmaceutical Industries, choose your preferred order type, and place the trade.
The Price-to-earnings (P/E) ratio of Sun Pharmaceutical Industries shares is 38.18. You can compare it with the sector average for relative valuation.
The Price to Book (P/B) ratio Sun Pharmaceutical Industries shares is 5.34. Useful to assess the stock's value relative to its book value.
To assess Sun Pharmaceutical Industries’s valuation compare Sector P/E, P/B which are 63.94 & 3.3 with sector averages, along with growth rates and financial metrics.
The Market Cap of Sun Pharmaceutical Industries is 463071.65 CR. It indicates the company's size category and trading liquidity.
The 52 week high and low prices of Sun Pharmaceutical Industries share price is 2046.90 & 1548.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.
Sun Pharmaceutical Industries belongs to the Healthcare sector.
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
Open a Free Demat Account
+ Free 1st Year AMC
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Invest in SUNPHARMA
Account Opening Fee
AMC for 1st Year
Auto Square Off Charges
Call & Trade
Open a Free Demat Account
+ Free 1st Year AMC
+ Free 1st Year AMC